

Agnieszka Jagiello-Gruszfeld

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3687801/agnieszka-jagiello-gruszfeld-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25 papers	6,454 citations	13 h-index	32 g-index
32 ext. papers	7,197 ext. citations	7.1 avg, IF	4.39 L-index

#	Paper	IF	Citations
25	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.. <i>Journal of Geriatric Oncology</i> , 2022 ,	3.6	1
24	Trastuzumab biosimilar (Kanjinti) in breast cancer patients: One-center retrospective observational study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13015-e13015	2.2	
23	Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13070-e13070	2.2	0
22	Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. <i>Journal of Oncology</i> , 2020 , 2020, 7267083	4.5	5
21	Effects of Germline Mutations on Triple-Negative Breast Cancer Prognosis. <i>Journal of Oncology</i> , 2020 , 2020, 8545643	4.5	10
20	Prognostic and predictive value of neutrophil/lymphocyte ratio in patients with triple-negative and HER2-positive breast cancer undergoing neoadjuvant systemic therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12620-e12620	2.2	
19	Pathological outcomes of HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab or dual anti-HER2 therapy and carboplatin with docetaxel: A Maria Skłodowska-Curie National Research Institute of Oncology experience.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12655-e12655	2.2	
18	Clinical value of kinase Aurora-A serum level determination in patients with breast cancer qualified for neoadjuvant chemotherapy: Pilot study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12627-e12627	2.2	
17	Validation of the Van Nuys Prognostic Index in 737 patients with ductal carcinoma in situ (DCIS) treated at Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e12603-e12603	2.2	
16	Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM). <i>Journal of Neuro-Oncology</i> , 2018 , 138, 191-198	4.8	26
15	Improving Fertility Preservation in Breast Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018 , 7, 258	2.2	
14	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018 , 103, 147-154	7.5	38
13	Primary angiosarcoma of the breast-series of 11 consecutive cases-a single-centre experience. <i>Current Oncology</i> , 2018 , 25, e50-e53	2.8	20
12	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 904-916	21.7	330
11	Retracing Circulating Tumour Cells for Biomarker Characterization after Enumeration. <i>Journal of Circulating Biomarkers</i> , 2015 , 4, 5	3.3	4
10	Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy. <i>European Oncology and Haematology</i> , 2014 , 10, 107	0.1	8
9	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology, The</i> , 2011 , 12, 369-76	21.7	68

8	Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. <i>Gynecologic Oncology</i> , 2011 , 122, 350-5	4.9	17
7	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. <i>Journal of Clinical Oncology</i> , 2011 , 29, 149-56	2.2	188
6	A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. <i>Oncology</i> , 2010 , 79, 129-35	3.6	32
5	A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2339-46	2.5	39
4	Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4454-61	2.2	540
3	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 533-43	4.4	631
2	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. <i>Lancet, The</i> , 2007 , 370, 2103-11	4.0	1856
1	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <i>New England Journal of Medicine</i> , 2006 , 355, 2733-43	59.2	2641